Bio-Rad Q1 Revenues Up 2 Percent; Will Pay Up to $110M for GnuBio | GenomeWeb

NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues increased 2 percent as its Life Science sales spiked 3 percent year over year.

The company also disclosed that its acquisition of sequencing technology developer GnuBio, announced earlier this year, is worth up to $110 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.